Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Nathanson

Showing results (341-350 of 528) with videos related to

Pageof 53
Sort By:
JCI Insight|January 19, 2017
A patient-derived-xenograft platform to study BRCA-deficient ovarian cancersErin George, Hyoung Kim, Clemens Krepler, et al.
BMC Medical Ethics|April 1, 2026
A randomized study of digital versus genetic counselor return of actionable genetic research results to biobank participants (RESPECT3 study)Anuja Rajendra Godbole, Elisabeth Wood, Brian Egleston, et al.
Cell Reports. Medicine|October 8, 2021
<i>CCNE1</i> copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer modelsHaineng Xu, Erin George, Yasuto Kinose, et al.
Developmental Cell|May 26, 2022
A human breast atlas integrating single-cell proteomics and transcriptomicsG Kenneth Gray, Carman Man-Chung Li, Jennifer M Rosenbluth, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 13, 2012
Genetic susceptibility to type 2 diabetes and breast cancer risk in women of European and African ancestryNingqi Hou, Yonglan Zheng, Eric R Gamazon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2015
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination TherapiesClemens Krepler, Min Xiao, Katrin Sproesser, et al.
Autophagy|July 4, 2014
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanomaReshma Rangwala, Robert Leone, Yunyoung C Chang, et al.
Cancer Cell|December 16, 2010
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3KJessie Villanueva, Adina Vultur, John T Lee, et al.
JCO Precision Oncology|July 9, 2025
LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair GenesSriram Anbil, Nicholas J Seewald, E Gabriela Chiorean, et al.
Journal of Personalized Medicine|December 23, 2022
The Penn Medicine BioBank: Towards a Genomics-Enabled Learning Healthcare System to Accelerate Precision Medicine in a Diverse PopulationAnurag Verma, Scott M Damrauer, Nawar Naseer, et al.
Pageof 53

Showing results (341-350 of 528) with videos related to

Sort By:
Pageof 53
JCI Insight|January 19, 2017
A patient-derived-xenograft platform to study BRCA-deficient ovarian cancersErin George, Hyoung Kim, Clemens Krepler, et al.
BMC Medical Ethics|April 1, 2026
A randomized study of digital versus genetic counselor return of actionable genetic research results to biobank participants (RESPECT3 study)Anuja Rajendra Godbole, Elisabeth Wood, Brian Egleston, et al.
Cell Reports. Medicine|October 8, 2021
<i>CCNE1</i> copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer modelsHaineng Xu, Erin George, Yasuto Kinose, et al.
Developmental Cell|May 26, 2022
A human breast atlas integrating single-cell proteomics and transcriptomicsG Kenneth Gray, Carman Man-Chung Li, Jennifer M Rosenbluth, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 13, 2012
Genetic susceptibility to type 2 diabetes and breast cancer risk in women of European and African ancestryNingqi Hou, Yonglan Zheng, Eric R Gamazon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2015
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination TherapiesClemens Krepler, Min Xiao, Katrin Sproesser, et al.
Autophagy|July 4, 2014
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanomaReshma Rangwala, Robert Leone, Yunyoung C Chang, et al.
Cancer Cell|December 16, 2010
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3KJessie Villanueva, Adina Vultur, John T Lee, et al.
JCO Precision Oncology|July 9, 2025
LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair GenesSriram Anbil, Nicholas J Seewald, E Gabriela Chiorean, et al.
Journal of Personalized Medicine|December 23, 2022
The Penn Medicine BioBank: Towards a Genomics-Enabled Learning Healthcare System to Accelerate Precision Medicine in a Diverse PopulationAnurag Verma, Scott M Damrauer, Nawar Naseer, et al.
Pageof 53